U.S. Markets open in 7 hrs 9 mins

Apria, Inc. (APR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
21.76+0.19 (+0.88%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close21.57
Open21.50
Bid0.00 x 800
Ask0.00 x 800
Day's Range20.89 - 22.20
52 Week Range20.07 - 28.01
Volume133,243
Avg. Volume484,000
Market Cap766.189M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Apria Appoints Michael-Bryant Hicks as Executive Vice President, General Counsel, and Corporate Secretary
    GlobeNewswire

    Apria Appoints Michael-Bryant Hicks as Executive Vice President, General Counsel, and Corporate Secretary

    INDIANAPOLIS, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Apria, Inc. (the “Company” or “Apria”) (Nasdaq: APR) announced today that it has appointed Michael-Bryant Hicks as Executive Vice President, General Counsel, and Corporate Secretary. Hicks will be based in Apria’s corporate headquarters in Indianapolis. Hicks joins Apria from Elanco Animal Health, where he was Executive Vice President, General Counsel, and Corporate Secretary. Prior to Elanco, he served in public company general counsel roles at Mallinckrodt Pharmaceuticals and The Providence Service Corporation, overseeing all legal functions with both companies. The appointment of Hicks follows the retirement of 25-year Apria employee Raoul Smyth, who most recently served as Executive Vice President, General Counsel and Corporate Secretary. Smyth joined Apria in 1996 and directed the Company’s legal and regulatory functions since 2015, playing significant roles in multiple milestones, including the Company’s February 2021 initial public offering. “As one of Apria’s earliest employees, Raoul Smyth was woven into the fabric of the Company both professionally and personally, and we are incredibly grateful for all of his contributions over the years,” said Dan Starck, Chief Executive Officer at Apria. “His departure created the need for experienced and talented counsel, and we’re confident that Michael-Bryant Hicks’ extensive corporate legal experience in diverse sectors within healthcare is exactly what we require. We are thrilled to add Hicks’ wealth of expertise to the Apria family and look forward to all that he will bring to the Company.” About Apria Apria is a leading provider of integrated home healthcare equipment and related services in the United States, providing home respiratory therapy, obstructive sleep apnea treatment and negative pressure wound therapy. Its approximately 275 locations throughout the continental United States and Hawaii serve nearly 2 million patients each year. All of Apria’s locations are accredited by The Joint Commission. Forward-Looking Statements This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as “outlook,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “could,” “seeks,” “predicts,” “intends,” “trends,” “plans,” “estimates,” “anticipates” or the negative version of these words or other comparable words. These forward-looking statements include any statements regarding the Company’s proposed initial public offering. Such forward-looking statements are subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors include but are not limited to those described under “Risk Factors” in the Company’s registration statement relating to the initial public offering. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in the registration statement. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. Investor ContactsBob.East@westwicke.com Asher.Dewhurst@westwicke.com Media ContactsMark.Corbae@westwicke.com Kyle.Evans@westwicke.com

  • Barrons.com

    Signify Health, Apria, Bioventus, and LoanDepot Make Their Market Debuts

    Signify Health, Apria, Bioventus, and loanDepot began trading Thursday. LoanDepot jumped nearly 57%.

  • GlobeNewswire

    Apria Announces Pricing of Initial Public Offering

    INDIANAPOLIS, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Apria, Inc. (the “Company” or “Apria”) (Nasdaq: APR) announced today the pricing of its initial public offering of 7,500,000 shares of its common stock at a price to the public of $20.00 per share. The selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of common stock. The shares are expected to begin trading on the Nasdaq Global Select Market on February 11, 2021 under the symbol “APR.” The offering is expected to close on February 16, 2021, subject to customary closing conditions. Apria will not receive any net proceeds from the sale of its common stock by the selling stockholders, including from any exercise by the underwriters of their option to purchase additional shares of the common stock from the selling stockholders. Citigroup and Goldman Sachs & Co. LLC are acting as joint lead book-running managers for the offering. BofA Securities, J.P. Morgan and UBS Investment Bank are acting as joint book-running managers for the offering. Piper Sandler, Citizens Capital Markets, Fifth Third Securities and TD Securities are acting as co-managers for the offering. The proposed offering of these securities will be made only by means of a prospectus. When available, copies of the prospectus relating to the proposed initial public offering may be obtained from: Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-800-831-9146 or by email at prospectus@citi.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY, by telephone at 1-212-902-1171, by facsimile at 1-212-902-9316 or by email at prospectus-ny@ny.email.gs.com; BofA Securities, Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte NC 28255-0001, by telephone at 1-800-294-1322 or by email at dg.prospectus_requests@bofa.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at 1-866-803-9204 or by email at prospectus-eq_fi@jpmchase.com; or UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019, by telephone at (888) 827-7275 or by emailing ol-prospectus-request@ubs.com. A registration statement relating to these securities was filed with, and declared effective by, the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Apria Apria is a leading provider of integrated home healthcare equipment and related services in the United States, providing home respiratory therapy, obstructive sleep apnea treatment and negative pressure wound therapy. Its approximately 275 locations throughout the continental United States and Hawaii serve nearly 2 million patients each year. All of Apria’s locations are accredited by The Joint Commission. Forward-Looking Statements This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as “outlook,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “could,” “seeks,” “predicts,” “intends,” “trends,” “plans,” “estimates,” “anticipates” or the negative version of these words or other comparable words. These forward-looking statements include any statements regarding the Company’s proposed initial public offering. Such forward-looking statements are subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors include but are not limited to those described under “Risk Factors” in the Company’s registration statement relating to the initial public offering. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in the registration statement. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. Investor Contacts Bob.East@westwicke.comAsher.Dewhurst@westwicke.com